LOS ANGELES CAPITAL MANAGEMENT LLC

Position in ARCT — Arcturus Therapeutics Holdings Inc.

CIK 1177206 LOS ANGELES, CA

Position in ARCT

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$1,727

-$257 QoQ

Shares Held

257

0.0% QoQ

Ownership

0.001%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#122

of 133 holders

Holding Since

Jun 2021

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names. ARCT ranks #162 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	729,635	$219,642,024
2	HALO	Halozyme Therapeutics, Inc.	1,938,035	$151,689,999
3	CAI	Caris Life Sciences, Inc.	3,958,531	$70,541,022
4	INCY	Incyte Corp	578,986	$65,633,852
5	VRTX	Vertex Pharmaceuticals Inc / Ma	130,802	$64,973,277
6	EXEL	Exelixis, Inc.	1,159,457	$63,086,055
7	REGN	Regeneron Pharmaceuticals, Inc.	98,585	$61,471,690
8	RPRX	Royalty Pharma plc	877,674	$49,211,181

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,727	257	0.0%	Shares	Sole	2026-08-13
2026-03-31	$1,984	257	-89.1%	Shares	Sole	2026-05-08
2025-12-31	$14,485	2,363	-90.1%	Shares	Sole	2026-02-11
2024-12-31	$404,021	23,808	+1.6%	Shares	Sole	2025-02-04
2024-09-30	$543,879	23,433	+121.7%	Shares	Sole	2024-11-04
2023-06-30	$303,204	10,572	-14.2%	Shares	Sole	2023-08-03
2023-03-31	$295,358	12,322	0.0%	Shares	Sole	2023-05-04
2022-12-31	$208,981	12,322	0.0%	Shares	Sole	2023-02-06
2022-09-30	$182,612	12,322	0.0%	Shares	Sole	2022-11-02
2022-06-30	$193,948	12,322	-79.3%	Shares	Sole	2022-08-05
2022-03-31	$1,607,624	59,630	+613.5%	Shares	Sole	2022-05-06
2021-06-30	$282,800	8,357	—	Shares	Sole	2021-08-05
No filing history on record for this holder in this stock.